H.C. Wainwright analyst Ed Arce lowered the firm’s price target on Arbutus Biopharma to $5 from $6 and keeps a Buy rating on the shares post the Q4 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ABUS:
- Arbutus Biopharma Anticipates Key 2024 Milestones
- Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
- Arbutus Biopharma (ABUS) Q4 Earnings Cheat Sheet
- Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
- Biotech Alert: Searches spiking for these stocks today
